Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

83.3%

5 terminated/withdrawn out of 6 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

N/A

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00281125Phase 1Terminated

Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

Role: lead

NCT01125787Phase 2Terminated

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Role: lead

NCT01157130Not ApplicableUnknown

Breast Cancer Patients: A Breast Cancer Rehabilitation and Exercise Laboratory

Role: lead

NCT00886457Phase 1Terminated

5-aza-2-deoxycytidine With Pegylated Interferon-alfa 2B: A Phase I Study With Molecular Correlates

Role: lead

NCT00880867Phase 1Terminated

Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma

Role: lead

NCT01131247Phase 2Withdrawn

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Role: lead

All 6 trials loaded